国有资产分级管理模式中政企联系度的比较

借助于“政企联系度－政府管理成本”模型,本文运用实证分析方法,从国有资产经营公司的政府管理成本角度比较分析了青岛、深圳在相似的国有资产分级管理模式中实际的政企关系和政企分开程度,并就如何优化国有资产分级管理模式和促进政企分开提出了相应的对策建议。     

Estimating the economic benefits of acidic rock drainage clean up using cost shares

This paper reports the results of a stated preference study that estimates the economic value for cleaning up acid rock drainage in Colorado's Snake River watershed. In contrast to much of the existing literature, the present study emphasizes benefit estimation for three implementing projects rather than benefit estimation for general changes in water quality or large scale water quality policy. The focus on implementing projects delivers information that is specifically relevant to current decisions being faced in the watershed. While valuation questions in most stated preference studies present costs that have no relation to actual project costs, this study presents a new cost share approach. Project costs are estimated and then valuation questions present different local cost shares to subjects. This approach facilitates stated cost variation necessary for estimating the mean of the distribution of project values without resorting to experimentally designed, fictitious stated costs. In addition to estimating the mean value, which facilitates benefit cost analysis, the study also provides median value estimates, which provide insights into the political feasibility of these projects. Study results suggest that local cost shares on the order of 20%-40%, depending on the project, are politically feasible.     

Diffusion in complex social networks

This paper studies how a behavior spreads in a population. We consider a network of interacting agents whose actions are determined by the actions of their neighbors, according to a simple diffusion rule. We find, using a mean-field approach, the threshold for the spreading rate above which the behavior spreads and becomes persistent in the population. This threshold crucially depends on the connectivity distribution of the social network and on specific features of the diffusion rule.     

高新技术产业投资、沉淀成本与补偿制度创新

高新技术产业投资对我国国民经济发展具有重要的作用和潜在的扩张力,但由于没有充分利用高新技术产业投资,严重影响国民经济的整体发展.为此,本文从沉淀成本角度出发,使用一个动态的投资模型,探讨高新技术产业投资所面临的障碍以及提供刺激高新技术产业投资的基本原则,在于完善投资成本补偿机制:一方面,需要大力完善市场制度;另一方面,更需要大力完善非市场制度,同时,政府折旧和税收政策等也是不可替代的.     

Contracting inside an organization: An experimental study

In this paper we propose and test a contracting mechanism, Multi-Contract Cost Sharing (MCCS), for use in the management of a sequence of projects. The mechanism is intended for situations where (1) the contractor knows more about the true costs of various projects than does the contracting agency (adverse selection), and (2) unobservable effort on the part of the contractor may lead to cost reductions (moral hazard). The proposed process is evaluated in an experimental environment that includes the essential economic features of the NASA process for the acquisition of Space Science Strategy missions. The environment is complex and the optimal mechanism is unknown. The design of the MCCS mechanism is based on the optimal contract for a simpler related environment. We compare the performance of the proposed process to theoretical benchmarks and to an implementation of the current NASA ‘cost cap’ procurement process. The data indicate that the proposed MCCS process generates significantly higher value per dollar spent than using cost caps, because it allocates resources more efficiently among projects and provides greater incentives to engage in cost-reducing innovations. Electronic Supplementary Material Supplementary material is available in the online version of this article at . JEL Classification C72, C92, D82, L32     

Characterization of additive cost sharing methods

The set of additive cost sharing methods when individual demands are integer valued and cost shares are non negative is characterized by its extreme points and by a network flow representation. The extreme methods allocate costs incrementally along a chain of demand vectors independent of the cost function. The result generalizes Wang’s characterization in that we do not assume the Dummy axiom.     

Cost sharing with multiple technologies

We study cost sharing problems where gains from cooperation can come from the presence of other agents, such as when agents share their technologies. A simple model is built, where economies of scale are eliminated in order to study this effect. We use as the key axiom the property that, if an agent does not improve the technology of any coalition he joins, he should not get any part of the gain from cooperation. With properties of linearity and symmetry, this axiom characterizes a well-defined set of rules. From this set, we propose a rule derived from the familiar Shapley value. We show that it is the only rule in that set satisfying an upper-limit property on individual cost allocations or a monotonicity property when technology improves. We also derive a distinct rule using a property that ensures that no coalition has an incentive to manipulate the individual demands of its members.     

Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score

Abstract

Background:

Personalized medicine requires diagnostic tests that stratify patients into distinct groups that may differentially benefit from targeted treatment approaches. This study compared the costs and benefits of two approaches for identifying those at high risk of developing type 2 diabetes for entry into a diabetes prevention program. The first approach identified high risk patients using impaired fasting glucose (IFG). The second approach used the PreDx Diabetes Risk Score (DRS) to further stratify IFG patients into high-risk and moderate-risk groups.

Methods:

A Markov model was developed to simulate the incidence and disease progression of diabetes and consequent costs and quality-adjusted life expectancy (QALY), comparing alternative approaches for identifying high-risk patients. We modeled direct medical costs, including the costs of the stratification testing, over a 10-year time horizon from a US payer perspective.

Results:

Stratification of IFG patients by the DRS method leads to improved identification and prevention among those at highest risk. At 5 years, the number needed to treat (NNT) in the IFG-only approach was 39 patients to prevent one case of diabetes compared to an NNT of 15 in the IFG?+?DRS approach. When compared to IFG alone, the IFG?+?DRS approach results in an incremental cost-effectiveness ratio (ICER) of $17,100/QALY gained at 5 years and would become cost saving in 10 years. In contrast and as compared to no stratification, the IFG-only approach would produce an ICER of $235,500/QALY gained at 5 years and $94,600/QALY gained at 10 years. The study findings are limited by the generalizability of the DRS validation study and uncertainty regarding the long-term effectiveness of diabetes prevention.

Conclusions:

The analysis indicates that the cost-effectiveness of diabetes prevention can be improved by better identification of patients at highest risk for diabetes using the DRS.     

The supply of education quality in a spatial model with asymmetric moving costs

The paper analyses the characteristics of the supply of higher education in different geographical macroareas using a strategic interaction framework. It focuses on universities operating in centralised funding system that autonomously set the quality of education showing that in equilibrium it is inversely related to students’ moving costs across areas. We show that in the presence of asymmetric information about workers’ ability and asymmetric costs of moving, the only PBE consistent with forward induction involves that only high ability workers acquire education and the quality of education is lower in macroareas where the moving costs are higher. Our model predicts that in economies with centralised university funding, educational policies must be regulated according to the specific socioeconomic characteristics of the area. Direct subsidies to universities may be ineffective in improving the quality of education in the less developed areas. When regional disparities are not too big, efficiency gains may be obtained by reducing moving costs.     

Cost data quality considerations for eco-efficiency measures

Cost data are a central aspect of eco-efficiency measures, either as means to assess value of production, or, more directly, as one dimension of the efficiency ratio. Several aspects may affect the quality of cost data, among them definitions, time and space, and confidentiality issues. Somewhat surprisingly, cost data quality has received little attention in the field of sustainability and eco-efficiency so far. Even worse, perhaps, is the lack of tools suitable for a cost data quality assessment and management.This paper discusses parameters that affect cost data quality, and will then propose a pedigree matrix as a tool designed for managing cost data quality issues. The application of the matrix is described, also in combination with a previously proposed, and broadly used, pedigree matrix for environmental data quality management.     

我国区际产业转移与对接机制研究

区域协调发展理念下,区际产业转移与对接是促进产业结构调整升级的重要手段。基于区际产业转移与对接内涵、动力机制等既有研究,从考虑运输成本的“推-拉”模型与异质性企业区位选择效应的市场动力机制,以及信息不对称下强弱势政府间竞争博弈机制两个维度,剖析我国区际产业转移与对接内在机理。从创新顶层设计、发挥比较优势、降低交易成本3个方面探讨了促进区际产业转移与对接的政策保障措施。     

Efficient payments: How much do they cost for the Central Bank?

Previous works related to optimal denominations for coins and banknotes consider that the “principle of least effort” that defines an efficient payment is the most important criterion for two main reasons. Firstly, it is more convenient for transactors and, secondly, it limits the production costs of denominations incurred by the central bank. Exploiting production cost data for the U.S. currency system in 2010, we show using simulations that efficient payments actually increase the annual production costs of the Federal Reserve by $156 million. As a consequence, we raise a larger issue for central banks which consists in issuing an efficient denominational mix that is more convenient for transactors and that reduces the production costs of denominations.     

The direct medical costs of Huntington’s disease by stage. A retrospective commercial and Medicaid claims data analysis

Abstract

Objective:

This study quantified the direct healthcare costs and major cost drivers among patients with Huntington’s disease (HD), by disease stage in commercial and Medicaid databases.

Methods:

This retrospective database analysis used healthcare utilization/cost data for HD patients (ICD-9-CM 333.4) from Thomson Reuters’ MarketScan Commercial and Medicaid 2002–2009 databases. Patients were classified by disease stage (Early/Middle/Late) by a hierarchical assessment of markers of disease severity, confirmed by literature review and key opinion leader input. Costs were measured over the follow-up time of each patient with total costs per patient per stage annualized using a patient-year cost approach.

Results:

Among 1272 HD patients, the mean age was similar in commercial (752 patients) and Medicaid (520 patients) populations (48.5 years (SD?=?13.3) and 49.3 years (SD?=?17.2), respectively). Commercial patients were evenly distributed by stage (30.5%/35.5%/34.0%; Early/Middle/Late). However, most (74.0%) Medicaid HD patients were classified as Late stage. The mean total annualized cost per patient increased by stage (commercial: $4947 (SD?=?$6040)–$22,582 (SD?=?$39,028); Medicaid: $3257 (SD?=?$5670)–$37,495 (SD?=?$27,111). Outpatient costs were the primary healthcare cost component. The vast majority (73.8%) of Medicaid Late stage patients received nursing home care and the majority (54.6%) of Medicaid Late stage costs were associated with nursing home care. In comparison, only 40.6% of commercial Late stage patients received nursing home care, which contributed to only 4.6% of commercial Late stage costs.

Conclusions:

The annual direct economic burden of HD is substantial and increased with disease progression. More late stage Medicaid HD patients were in nursing homes and for a longer time than their commercial counterparts, reflected by their higher costs (suggesting greater disease severity). Key limitations include the classification of patients into a single stage, as well as a lack of visibility into full long-term care/nursing home-related costs for commercial patients.